IASO206 in Patients With Relapsed/Refractory Multiple Myeloma

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma

Trial Details

NCT ID
NCT07322159
Phase
EARLY_PHASE1
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • IASO206 injection
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • 18 to 75 years old, male or female;
  • Diagnosed with relapsed/refractory multiple myeloma (RRMM) according to IMWG criteria, and have received at least 2 lines of treatment including on…
  • Presence of measurable lesions during screening according to any of the following criteria:
  • Serum monoclonal protein (M-protein) level: ≥5 g/L f;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →